Project Details
Description
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer that requires treatment with highly intensive chemotherapy. The prognosis of patients with relapsed and refractory (treatment resistant) T-ALL is very poor. Dr. Ferrando and his team have identified that specific mutations in the NT5C2 gene lead to chemotherapy resistance in 20% of relapse T-ALL cases. The goal of this research is to generate a model of chemotherapy resistance driven by mutant NT5C2 genes and utilize this model to develop new tailored therapies for the treatment of relapsed T-ALL.
| Status | Finished |
|---|---|
| Effective start/end date | 7/1/13 → 6/30/14 |
Funding
- St. Baldrick's Foundation
ASJC Scopus Subject Areas
- Cancer Research
- Oncology
- Pediatrics, Perinatology, and Child Health
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.